发明公开
EP2197469A2 USE OF NF-KAPPAB INHIBITOR SN50 AND OPTIONALLY ANGIOTENSIN III AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG HBV INFECTION
审中-公开
NF-κB的SN50抑制剂在肝衰竭的治疗所引起的暴发性HBV感染USE
- 专利标题： USE OF NF-KAPPAB INHIBITOR SN50 AND OPTIONALLY ANGIOTENSIN III AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG HBV INFECTION
- 专利标题（中）： NF-κB的SN50抑制剂在肝衰竭的治疗所引起的暴发性HBV感染USE
-
申请号： EP08802060.7申请日： 2008-09-09
-
公开(公告)号： EP2197469A2公开(公告)日： 2010-06-23
- 发明人: BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
- 申请人： Mondobiotech Laboratories AG
- 申请人地址： Herrengasse 21 9490 Vaduz LI
- 专利权人： Mondobiotech Laboratories AG
- 当前专利权人： Mondobiotech Laboratories AG
- 当前专利权人地址： Herrengasse 21 9490 Vaduz LI
- 代理机构： Arth, Hans-Lothar
- 优先权： EP07017754 20070911
- 国际公布： WO2009039966 20090402
- 主分类号： A61K38/17
- IPC分类号： A61K38/17 ; A61K38/08 ; A61P31/20 ; A61P3/00 ; A61P9/00 ; A61P11/00 ; A61P25/28 ; A61P31/00 ; A61P35/00 ; A61P37/00 ; A61P31/18 ; A61P31/06
摘要：
The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
信息查询
IPC分类:
